{"id":15711,"date":"2019-04-22T16:28:16","date_gmt":"2019-04-22T07:28:16","guid":{"rendered":"https:\/\/hic.lne.st\/?p=15711"},"modified":"2019-04-26T22:05:55","modified_gmt":"2019-04-26T13:05:55","slug":"hic-osaka2019_medical","status":"publish","type":"post","link":"https:\/\/hic.lne.st\/en\/1tp3-te3-6\/1tp3-te71-tp3t831tp3-tb6-10\/15711\/","title":{"rendered":"Osaka Forum 2019] The New Leaders of Drugs Will Create the Future of Medicine \/ Saturday, May 18, 2019, 13:00 @ Osaka Nanko"},"content":{"rendered":"
panel discussion<\/span><\/span><\/div>\n
The New Leaders of Drugs Will Create the Future of Medicine
\n<\/span><\/strong><\/div>\n

Riverness will sponsor the event.Hyper Interdisciplinary Conference in Osaka Forum 2019<\/a>(Saturday, May 18, 2019), a panel discussion, \"New Leaders of Drugs Create the Future of Medicine\" (session partners: City of Kobe and Kobe Medical Industry Development Organization) will be held within the
\n<\/span>
\n<\/span><\/p>\n

Society for Hyperdisciplinarity Osaka Forum 2019 WEB:https:\/\/hic.lne.st\/conference\/osaka2019\/<\/a><\/b><\/strong><\/span><\/div>\n

 <\/p>\n

Drug discovery technology to realize new treatment concepts. Traditionally, the focus has been on low-molecular-weight compounds, but in recent years, new compto treatment methods such as antibody drugs, which have a large share of the new drug market, nucleic acid drugs, and regenerative medicine are coming into the world. In addition, digital medicines utilizing IoT technology are being implemented. In this session, venture companies working on new drug discovery utilizing nucleic acids and cells, and large companies that are beginning to work on healthcare using digital technology in addition to conventional drug discovery, will take the stage to explain the characteristics and actual conditions of their respective fields, and discuss the drugs that will play a role in future healthcare, while looking over these areas. The panelists will discuss the characteristics and actual conditions of each of these fields.
\n<\/span><\/span><\/p>\n

 <\/p>\n

We will have a program of discussions among researchers, venture companies, and large corporations from various perspectives, not limited to the themes of this session.
\nWe are currently accepting applications for audience participation and research poster presentations. Please visit the conference website (see below).<\/span><\/span>
\n<\/span><\/p>\n

Application:https:\/\/hic.lne.st\/conference\/osaka2019\/<\/a><\/b><\/strong><\/span><\/div>\n

 <\/p>\n

\n

The New Leaders of Drugs Will Create the Future of Medicine<\/span>
\nSession Partners Kobe City, Kobe Medical Industry Development Organization
\n<\/span><\/strong><\/span><\/p>\n

Date: Saturday, May 18, 2019, 13:00-14:00
\n<\/span>Venue: ATC Hall O's South 6F Conference Room (2-1-10 Nanko-Kita, Suminoe-ku, Osaka 559-0034, Japan)
\n<\/span>Closest Station: New Tram, Trade Center-mae Station
\nMap:https:\/\/atchall.com\/access<\/a><\/span><\/span><\/p>\n

 <\/p>\n

<Speakers<\/span><\/p>\n

\"\"<\/p>\n

Visiting Associate Professor, Graduate School of Science, Technology and Innovation, Kobe University
\nMr. Masanori Kataoka<\/strong>
\n<\/span>D. from Nagoya University. After working as a Research Assistant at Nagoya University, Assistant Professor at National Institutes of Natural Sciences, Specially Appointed Lecturer at Kochi University, and Visiting Professor at Kobe University, he established Shikoku Nucleic Acid Chemistry Co. in 2015, where he also serves as Director in charge of research. Specialties: nucleic acid chemistry, marine natural product chemistry, organometallic chemistry.<\/span><\/span><\/p>\n

 <\/p>\n

\"\"<\/p>\n

Director and COO, Cell Fiber Inc.
\n<\/strong>Yu Yanagisawa<\/strong>
\n<\/span>Graduated from Tokyo University of Pharmacy and Life Sciences, Faculty of Life Sciences, Department of Environmental Life Sciences. D. (Engineering), Department of Chemical and Biological Engineering, Graduate School of Chemical and Biological Engineering, The University of Tokyo. engaged in planning and development work at RIVANES Corporation until March 2011. in March 2018, received the Dean's Award of the Graduate School of Engineering, The University of Tokyo and the President's Award of The University of Tokyo. since May 2018, appointed as Director of Cell Fiber. since June 2018, AMED \"Cell Development of High Density Continuous Production Technology for Antibody Production Using Fiber\" Principal Investigator.<\/span><\/span><\/p>\n

 <\/p>\n

\"\"<\/p>\n

Director, Open Innovation Center, Bayer Yakuhin K.K.
\n<\/strong>Shunichi Takahashi<\/strong>
\n<\/span>Joined Mitsui Pharmaceutical Industries, Ltd. in 1993 as a researcher in the Drug Discovery Laboratory. In 2001, he joined Nihon Schering K.K., and from 2001 to 2007, he was seconded to Berlex Biosciences (US company of Schering AG), where he worked as a researcher in the Cardiovascular Research Department and Immunology Research Department. In 2007, he joined Bayer Yakuhin K.K. as a researcher in the Cardiovascular Research Division and the Immunology Research Division. He joined Bayer in 2007 as a senior researcher in the Stem Cell Drug Discovery Department of the Regenerative Medicine Research Division, as a manager in the cardiovascular area of Project Management in the Development Division, and as a manager in the Primary Care Department of the Medical Affairs Division, before assuming his current position in June 2014.<\/span><\/span><\/p>\n

 <\/p>\n

.<\/span><\/p>\n

\"\"<\/strong><\/span><\/p>\n

Director, Knowledge Foundation Research Center, Liverness, Inc.
\n<\/strong>Hiroyuki Takahashi<\/strong>
\n<\/span>D. from Yokohama City University in 2009. D. in Science. At RIVERNESS Corporation, he is engaged in creating new research projects between industry and researchers, including the launch of the \"RIVERNESS Research Fund\" for young researchers. In addition, he continues to organize \"super interdisciplinary academic societies\" where the enthusiasm for science and technology of individual people, from elementary and junior high school students to university students, teachers, companies, and local factories, are combined to generate new knowledge and seeds for research and development.
\n<\/span><\/span><\/p>\n

 <\/p>\n

------------ Society for Hyperdisciplinarity Osaka Forum 2019 Overview ------------<\/span><\/strong><\/p>\n

Conference theme: Creating a new axis of medicine, food and housing - Omoroi Future Blueprint from Kansai<\/span>
\nDate and time of the event:<\/span>
\nFriday, May 17, 19:00 - 21:00 (Reception)<\/span>
\nSaturday, May 18, 09:00-18:00 (Forum)<\/span>
\nOrganized by: Liverness Co.<\/span>
\nLocation: ATC Hall O's South 6F Conference Room<\/span>
\nParticipation fee: Free for academics and presenters, 50,000 yen for companies<\/span>
\n\u3000\u3000\u3000\u3000*Free of charge for partners and those willing to serve as judges<\/span>
\nConvention URL:https:\/\/hic.lne.st\/conference\/osaka2019\/<\/a><\/span><\/p>\n

 <\/p>\n

\uff1cContact us for more information.<\/span>
\nLIVANES Corporation Osaka Head Office (Attn: Fukuda, Isogai)<\/span>
\nTEL\uff1a050-1743-9799 E-mail\uff1ahic@Lnest.jp<\/span><\/p>","protected":false},"excerpt":{"rendered":"

Panel Discussion New Leaders in Drugs Make the Future of Medicine Within the Osaka Forum 2019 (Saturday, May 18, 2019) of the Society of Transdisciplinary Studies, hosted by Livanes, a panel discussion \"New Leaders in Drugs Make the Future of Medicine [...]...<\/p>","protected":false},"author":32,"featured_media":15864,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"","footnotes":""},"categories":[1],"tags":[],"year_conference":[],"acf":[],"aioseo_notices":[],"modified_by":"\u677e\u539f \u5c1a\u5b50","_links":{"self":[{"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/posts\/15711"}],"collection":[{"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/comments?post=15711"}],"version-history":[{"count":5,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/posts\/15711\/revisions"}],"predecessor-version":[{"id":15716,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/posts\/15711\/revisions\/15716"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/media\/15864"}],"wp:attachment":[{"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/media?parent=15711"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/categories?post=15711"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/tags?post=15711"},{"taxonomy":"year_conference","embeddable":true,"href":"https:\/\/hic.lne.st\/en\/wp-json\/wp\/v2\/year_conference?post=15711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}